Program Description: 

The field of Pediatric Surgery is continuously advancing.  Pediatric surgeons have to stay current in the methods of evaluation and techniques of surgery in order to provide best care for infants and children at a tertiary level and to teach residents and fellows.  Additionally, the field of research in Pediatric health care must keep pace with current clinical developments.  Ideally, this conference would bring together research and clinical concepts to achieve advances in patient care.

Continuing education is essential for staying current and up to date for all faculty and employees at the Medical College of Wisconsin and Children’s Hospital of Wisconsin. The fields of Surgery and basic research are advancing at an alarming rate.  One of the best ways of staying current is to have focused studies of cutting edge research presented by experts in the field. Faculty and employees who attend our conferences will be better educated, understand the current state of the art and as a result be much more competent faculty and employees. 
 
The main goal of this conference is to increase dialogue between clinical staff and bench researchers, and see an increased number of collaborations between these two groups.
 

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Medical College of Wisconsin designates this activity for up to 1.5 hours of participation for continuing education for allied health professionals.  

 

Target audience: 

Pediatric Surgery faculty and staff

Learning objectives: 
  1. Establish the clinical, genetic, and pathological features of X-linked myotubular myopathy (XLMTM).
  2. Introduce the concept of hypertrophic therapy in the context of myostatin/activin type IIB receptor inhibition, and the limitations of this strategy in murine XLMTM.
  3. Establish the advantages and disadvantages of gene- and protein-replacement strategies, and the efficacy of these strategies murine and canine XLMTM.

 

Faculty & credentials: 

Speaker

Michael Lawlor, MD, PhD

Assistant Professor

Department of Pathology

Division of Pediatric Pathology

Medical College of Wisconsin

Disclosures:  Consultant for Sarepta Therapeutics; research in laboratory is performed, in part, using funding from Sponsored Research Agreements with Audentes Therapeutics and Valerion Therapeutics

 

 

Kirkwood Pritchard, Ph.D. (Activity Director)

Keith Oldham, MD  (Planner)

Meghann Sytsma (Coordinator)

 

Contact

Name: 
Meghann Sytsma
Phone number: 
+1 (414) 955-2538
Session date: 
10/14/2014 - 5:00pm to 6:30pm CDT
Location: 
Children's Corporate Center
999 92nd St
Suite 220
Milwaukee, WI 53226
United States
  • 1.50 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.50 Hours of Participation
    Hours of Participation credit.

Please login or register to take this course.